Clinical trials: Trametinib
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04527549
- Testing
- Dabrafenib mesylate, Hydroxychloroquine, Trametinib dimethyl sulfoxide
- Where
- 199 sites in United States
- Volunteers
- 5 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Differentiated Thyroid Cancer (DTC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the…
- Trial name
- NCT04940052
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Special Drug Use-results Surveillance of Tafinlar/Mekinist
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
- Trial name
- NCT06262919
- Testing
- Tafinlar/Mekinist
- Where
- 70 sites in Japan
- Volunteers
- 110 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
This phase Ib/II trial studies the side effects and best dose of trametinib when given together with pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer that has come back and spread…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03225664
- Testing
- Pembrolizumab, Pharmacokinetic Study, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Absolute Bioavialability of GSK1120212
A Phase I, single-center, open-label, single-persiod, combined single dose oral and IV microtracer study in subjects with solid tumors.
- Trial name
- NCT01416337
- Testing
- GSK1120212, GSK1120212B
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Advanced and Selected Solid Tumors
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and /or recommended phase II dose (RP2D) and schedule for the PI3K (Phosphatidylinositol 3-Kinase) inhibitor BKM120 given…
- Trial name
- NCT01155453
- Testing
- BKM120, GSK1120212
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 113 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.
- Trial name
- NCT03580382
- Testing
- Trametinib daily Until PD, CDX-3379 (ERBB3 antibody)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Solid Tumours
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose.
- Trial name
- NCT00687622
- Testing
- GSK1120212
- Where
- 12 sites in United States
- Volunteers
- 206 people
- Sponsor
- GlaxoSmithKline
Cancer
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
Present clinical study will be conducted in China to evaluate the pharmacokinetics of single and repeat oral doses of trametinib, the safety profile and the clinical activity in Chinese subjects with solid tumor.
- Trial name
- NCT02939846
- Testing
- Trametinib
- Sponsor
- GlaxoSmithKline
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
This randomized phase I trial studies how well trametinib with or without GSK 2141795 (protein kinase B [Akt] inhibitor GSK2141795) works in treating patients with endometrial cancer that has come back (recurrent) or does not go…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01935973
- Testing
- Laboratory Biomarker Analysis, Trametinib, Uprosertib
- Where
- 22 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.
- Trial name
- MERAIODE (NCT03244956)
- Testing
- Trametinib, Dabrafenib, 131I
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Lung Cancer Stage III, Mutation
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- NUMER (NCT06563999)
- Testing
- Sunvozertinib, Crizotinib, Pralsetinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Vascular Anomalies
Trametinib Treatment for Complicated Vascular Anomalies
Complicated vascular anomalies have diverse etiologies and variable clinical manifestations, and no standardized treatment protocol has been established.
- Trial name
- NCT07072403
- Testing
- Trametinib tablet
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Multiple Myeloma
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: Trametinib Dabrafenib
- Trial name
- NCT03091257
- Testing
- Dabrafenib, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Solid Tumor
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of HLX208 (BRAF V600E inhibitor) in combination with trametinib in patients with advanced solid tumors
- Trial name
- NCT04965220
- Testing
- HLX 208
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic NRAS Melanoma
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma
Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab).
- Trial name
- CHLOROTRAMMEL (NCT03979651)
- Testing
- Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)
- Where
- 5 sites in France
- Volunteers
- 29 people
- Sponsor
- Hospices Civils de Lyon
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a…
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02551718
- Testing
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT02910700
- Testing
- Binimetinib, Dabrafenib, Encorafenib
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer.
- Trial name
- NCT01192165
- Testing
- Trametinib (GSK1120212), Docetaxel, Erlotinib
- Where
- 20 sites in United States, Canada and 2 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline